EDISON, N.J.,, Aug. 18 /PRNewswire/ -- Digitek Medication: Digitek (digoxin tablets) is a widely-used medication used to treat various heart conditions, such as abnormal heart rhythms (atrial fibrillation & atrial flutter), and heart failure. Digitek is a powerful drug, which is so potent that even a slight increase in dosage can be toxic or fatal.
If you or a loved one has suffered digitalis toxicity or symptoms associated with digitalis toxicity as a result of taking Digitek, you should contact Eichen Levinson & Crutchlow (http://www.eichenlevinson.com/) to evaluate your claim. You may be entitled to compensation for medical expenses, loss of wages, and pain and suffering. Eichen's Digitek attorneys are able to handle and litigate Digitek cases no matter where you live
Digitek Recall: Following repeated Food and Drug Administration (FDA) criticisms of its manufacturing processes, the pharmaceutical company, Actavis Totowa issued a Class I nationwide drug recall for all lots of Digitek (digoxin) on the grounds that some tablets may contain twice the approved level of the active ingredient. A Class I recall is the most dangerous type of FDA recall. Even though the drugs are sold under different brand names, they are essentially the same product with the same active ingredient. Therefore, the recall pertains to Digitek tablets (all strengths) distributed by Mylan Pharmaceuticals and sold under the label "Bertek", as well as Digitek distributed by UDL Laboratories, Inc. and sold under the label "UDL".
Digitalis Toxicity Signs & Symptoms may include the following:
To evaluate your Digitek claim, contact Eichen Levinson & Crutchlow, with offices located in Edison, New Jersey and Toms River, New Jersey, provides award-winning legal services in the tri-state area and nationally in matters involving catastrophic personal injury, mass torts, medical malpractice, class actions, and consumer fraud litigation.
Contact: Angela McKillop Amckillop@eichenlevinson.com EichenLevinson .com Tel: (732) 777-0100 Fax: (732) 248-8273
|SOURCE Eichen Levinson & Crutchlow, LLP|
Copyright©2009 PR Newswire.
All rights reserved